FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC)
Publication
, Conference
Gourley, C; Miller, A; Paul, J; Carty, K; Rodgers, W; Millan, D; Connolly, K; Gabra, H; Banerjee, S; Coleman, R; Moore, KN; Secord, AA ...
Published in: International Journal of Gynecological Cancer
November 2025
Duke Scholars
Published In
International Journal of Gynecological Cancer
DOI
ISSN
1048-891X
Publication Date
November 2025
Volume
35
Issue
11
Start / End Page
102736 / 102736
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Gourley, C., Miller, A., Paul, J., Carty, K., Rodgers, W., Millan, D., … Gershenson, D. (2025). FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC). In International Journal of Gynecological Cancer (Vol. 35, pp. 102736–102736). Elsevier BV. https://doi.org/10.1016/j.ijgc.2025.102736
Gourley, Charlie, Austin Miller, Jim Paul, Karen Carty, William Rodgers, David Millan, Kathryn Connolly, et al. “FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC).” In International Journal of Gynecological Cancer, 35:102736–102736. Elsevier BV, 2025. https://doi.org/10.1016/j.ijgc.2025.102736.
Gourley C, Miller A, Paul J, Carty K, Rodgers W, Millan D, et al. FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC). In: International Journal of Gynecological Cancer. Elsevier BV; 2025. p. 102736–102736.
Gourley, Charlie, et al. “FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC).” International Journal of Gynecological Cancer, vol. 35, no. 11, Elsevier BV, 2025, pp. 102736–102736. Crossref, doi:10.1016/j.ijgc.2025.102736.
Gourley C, Miller A, Paul J, Carty K, Rodgers W, Millan D, Connolly K, Gabra H, Banerjee S, Coleman R, Moore KN, Secord AA, O’Malley D, Dorigo O, Gaillard S, Waggoner S, Wolfson A, Edelson M, Hagemann A, Guntupalli S, Huang H, Wenzel L, Gershenson D. FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC). International Journal of Gynecological Cancer. Elsevier BV; 2025. p. 102736–102736.
Published In
International Journal of Gynecological Cancer
DOI
ISSN
1048-891X
Publication Date
November 2025
Volume
35
Issue
11
Start / End Page
102736 / 102736
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis